Suppression of RAC1-driven malignant melanoma by Group A PAK inhibitors


Activating mutations in the RAC1 gene have recently been discovered as driver events in malignant melanoma. Expression of this gene is associated with melanocyte proliferation, and melanoma cells bearing this mutation are insensitive to BRAF inhibitors such as vemurafenib and dabrafenib, and also may evade immune surveillance due to enhanced expression of… (More)
DOI: 10.1038/onc.2017.400

8 Figures and Tables


  • Presentations referencing similar topics